EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #72622_C
PPARγ激活剂
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
总览
罗格列酮（Rosiglitazone）是一种强效且选择性的PPARγ配体。它与PPARγ配体结合结构域结合，Kd值为43 nM（Lehmann et al.）。它激活基于荧光素酶的表达载体PPARγ1和PPARγ2，EC50值分别约为30 nM和100 nM （Lehmann et al.）。
维持和自我更新
·刺激小鼠胚胎神经干细胞增殖并抑制神经元分化（Wada et al.）。
分化
·诱导C3H10T1/2干细胞的脂肪细胞分化（Lehmann et al.）。
·促进血管生成祖细胞的内皮细胞分化，并抑制平滑肌细胞分化（Wang et al.）。
·刺激小鼠和人骨髓间充质干细胞的脂肪细胞分化，并降低成骨作用(Ali et al.; Benvenuti et al.; Lecka-Czernik et al.; Sorocéanu et al.)。
·增强 RANKL 和 M-CSF 刺激的小鼠骨髓细胞破骨细胞形成（Wu et al.）。
细胞类型
脂肪细胞，血管生成细胞，间充质干/祖细胞，神经干/祖细胞
种属
人，小鼠，非人灵长类，其它细胞系，大鼠
应用
分化，扩增
研究领域
神经科学，干细胞生物学
CAS 编号
122320-73-4
化学式
C₁₈H₁₉N₃O₃S
纯度
≥98%
通路
PPARγ
靶点
PPARγ
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (1)
文献 (8)
Regulation of selective PPARγ modulators in the differentiation of osteoclasts. Journal of cellular biochemistry 2013 SEP
Abstract
Diabetes is the most common chronic disease in the world and causes complications with many diseases, such as heart disease and osteoporosis. Osteoporosis is a systemic bone disease characterized by imbalance in bone resorption and bone formation. Osteoclast is type of bone cell that functions in bone resorption and plays a critical role in bone remodeling. Rosiglitazone and pioglitazone, which belong to Thiazolidinediones(TZDs), are commonly used antidiabetic drugs. As PPARγ full agonists, they can activate PPARγ in a ligand-dependent way. Recent studies indicate that these PPARγ full agonists have some side effects, such as weight gain and bone loss, which may increase the risk of osteoporosis. In contrast, selective PPARγ Modulators (SPPARγMs) are novel PPARγ ligands that can activate PPARγ in different ways and lead to distinct downstream genes. Mice bone marrow cells were stimulated with recombinant mouse RANKL and M-CSF to generate osteoclasts. To determine the effect on osteoclasts formation, PPARγ ligands (Rosiglitazone, Fmoc-L-Leu, and Telmisartan) were added at the beginning of the culture. Rosiglitazone significantly increased the differentiation of multinucleated osteoclasts, while osteoclasts formation triggered by SPPARγMs was much less than that displayed by rosiglitazone. We found that the enhancement of PPARγ ligands may be associated with TRAF6 and downstream ERK signal pathway. We also demonstrated osteoclasts show characteristic M2 phenotype and can be further promoted by PPARγ ligands, especially rosiglitazone. In conclusion, reduced osteoclasts differentiation characteristic of SPPARγMs highlights SPPARγMs potential as therapeutic targets in diabetes, versus traditional antidiabetic drugs.
Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. Journal of endocrinological investigation 2007 OCT
Abstract
Thiazolidinediones (TZD) are widely prescribed for the treatment of Type 2 diabetes. Increased loss of bone mass and a higher incidence of fractures have been associated with the use of this class of drugs in post-menopausal women. In vitro studies performed in rodent cell models indicated that rosiglitazone (RGZ), one of the TZD, inhibited osteoblastogenesis and induced adipogenesis in bone marrow progenitor cells. The objective of the present study was to determine for the first time the RGZ-dependent shift from osteoblastogenesis toward adipogenesis using a human cell model. To this purpose, bone marrow-derived mesenchymal stem cells were characterized and induced to differentiate along osteogenic and adipogenic lineages. We found that the exposure to RGZ potentiated adipogenic differentiation and shifted the differentiation toward an osteogenic phenotype into an adipogenic phenotype, as assessed by the appearance of lipid droplets. Accordingly, RGZ markedly increased the expression of the typical marker of adipogenesis fatty-acid binding protein 4, whereas it reduced the expression of Runx2, a marker of osteoblastogenesis. This is the first demonstration that RGZ counteracts osteoblastogenesis and induces a preferential differentiation into adipocytes in human mesenchymal stem cells.
Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation. The Journal of biological chemistry 2006 MAY
Abstract
Peroxisome proliferator-activated receptor gamma (PPARgamma) plays an important role in insulin sensitivity, tissue homeostasis, and regulating cellular functions. We found high-level expression of PPARgamma in embryo mouse brain and neural stem cells (NSCs), in contrast to extremely low levels in adult mouse brain. Here, we show that PPARgamma mediates the proliferation and differentiation of murine NSCs via up-regulation of the epidermal growth factor receptor and activation of the ERK pathway. Cell growth rates of NSCs prepared from heterozygous PPARgamma-deficient mouse brains, PPARgamma-RNA-silenced NSCs, and PPARgamma dominant-negative NSCs were significantly decreased compared with those of wild-type NSCs. Physiological concentrations of PPARgamma agonists, rosiglitazone and pioglitazone, stimulated NSC growth, whereas antagonists caused cell death in a concentration-dependent manner via activation of the caspase cascade. The stimulation of cell growth by PPARgamma was associated with a rapid activation of the ERK pathway by phosphorylation and up-regulation of epidermal growth factor receptor and cyclin B protein levels. In contrast, activation of PPARgamma by agonists inhibited the differentiation of NSCs into neurons. The inhibition of differentiation was associated with an activation of STAT3. These data indicate that PPARgamma regulates the development of the central nervous system during early embryogenesis via control of NSC proliferation.
更多信息
| 种属 | Human, Mouse, Non-Human Primate, Other, Rat |
|---|---|
| Cas Number | 122320-73-4 |
| Chemical Formula | C₁₈H₁₉N₃O₃S |
| 纯度 | ≥ 98% |
| Target | PPARγ |
| Pathway | PPARγ |
相关产品
-
MesenCult™ 脂肪分化试剂盒 (人)人MSCs向脂肪细胞分化的培养基
-
NeuroCult™ SM1 神经添加物无血清神经添加物（50X）
